There were hopes that very soon, a drug will land into markets, which will prevent the plaque to buildup in brain and further slow down the progression of Alzheimer's disease. But according to some recent information, the company has failed to develop it successfully and has therefore ended with its designing.

Pfizer Inc. and Johnson & Johnson were behind the intravenous formulation of this experimental Alzheimer's disease drug bapineuzumab. But during the second late-stage trial, it didn't work out positively. There were no effective results seen in patients with mild to moderate forms of the disease. And therefore on Monday, they announced to suspend the project.

As far as the penalty is concerned, Johnson & Johnson has agreed to take a charge of up to $400 million in the third quarter. At the same time, Elan Corp. PLC, that was responsible for giving a license to Johnson & Johnson for manufacturing this drug, will take a charge of $117.3 million.

It is believed that amyloid is a protein that brings toxic effects on the brain of an individual and therefore is known as the common cause of Alzheimer. Targeting the same, Bapineuzumab was developed. But with the failure of it, several questions have been arising towards this theory of brain and its protein.